BRIEF—Vedanta Biosciences raises $45.5 million in series C round

PureTech Health affiliate Vedanta Biosciences has raised an additional $18.5 million as part of its series C financing round, bringing the total for the round to $45.5 million.

The money will be used to advance Vedanta’s clinical portfolio in indications including food allergy, advanced or metastatic cancers, and infection. The firm is also collaborating with Johnson & Johnson’s pharma arm, Janssen, on an inflammatory bowel disease candidate.

Vedanta is developing a range of bacterial strains designed to produce a therapeutic impact on people’s gut microbiota.